Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the FDA's acceptance of its new drug application (NDA) for roflumilast cream, targeting adults and adolescents with psoriasis. The PDUFA target action date is set for July 29, 2022. The NDA is backed by positive results from pivotal Phase 3 studies, DERMIS 1 and 2, which demonstrated significant efficacy compared to placebo. If approved, roflumilast cream will be the first topical PDE4 inhibitor for psoriasis, aiming to improve treatment options for patients.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the appointment of Mas Matsuda as General Counsel and Corporate Secretary, succeeding Keith Klein, who is retiring after 30 years in the industry. Matsuda, previously at Halozyme, brings over 20 years of legal expertise, which will aid in Arcutis' focus on growing its pipeline of therapies for immune-mediated skin diseases. Notably, the company is preparing for the potential approval of topical roflumilast cream for psoriasis and ongoing pivotal studies across multiple dermatological conditions.

Arcutis Biotherapeutics (Nasdaq: ARQT) presented data at the RAD Conference indicating their proprietary cream vehicle for atopic dermatitis demonstrated similar moisturizing effects compared to a commercial ceramide moisturizer. The study involved 40 patients with mild eczema, showing no significant changes in transepidermal water loss (TEWL), suggesting both products were non-damaging. Patient assessments highlighted comparable improvements in skin conditions like dryness and irritation. The study supports ongoing investigations into roflumilast cream for treating atopic dermatitis.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced its participation in the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 1:00 p.m. EST. This late-stage biopharmaceutical company focuses on innovations in immuno-dermatology to improve treatment for patients with immune-mediated dermatological diseases. The conference will be virtual, and webcasts can be accessed on the company's website. Arcutis aims to revolutionize care for conditions like plaque psoriasis and atopic dermatitis, with key data readouts expected by the end of 2022.

Arcutis Biotherapeutics has submitted a New Drug Application (NDA) for roflumilast cream targeting plaque psoriasis. They are also initiating Phase 3 trials for roflumilast foam in scalp and body psoriasis and atopic dermatitis. The company holds a strong financial position with approximately $370 million in cash and securities, sufficient to fund operations into 2023. However, R&D and G&A expenses have significantly increased, resulting in a net loss of $57 million for Q3 2021. Positive outcomes from ongoing trials could pave the way for multiple product launches within 2022.

Arcutis Biotherapeutics (Nasdaq: ARQT) has submitted a New Drug Application (NDA) to the FDA for its non-steroidal treatment, roflumilast cream, aimed at treating plaque psoriasis. This cream is poised to be the first topical PDE4 inhibitor if approved. In Phase 3 studies, roflumilast cream showed significant improvements over placebo in key endpoints related to psoriasis treatment and was well-tolerated. The treatment offers a promising option for patients, addressing challenges posed by current therapies.

Arcutis Biotherapeutics (ARQT) announced promising Phase 3 results for its topical roflumilast cream, demonstrating significant reductions in itch severity and burden in chronic plaque psoriasis patients. Data revealed that quality of life improvements began as early as week two. Roflumilast cream showed a 42.4% success rate in the Investigator Global Assessment compared to 6.1% for the vehicle. Additionally, the Phase 2 studies indicated strong efficacy in seborrheic dermatitis and scalp psoriasis. These findings support the potential of roflumilast as a non-steroidal treatment option.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced a new patent from the U.S. Patent and Trademark Office, enhancing protection for its topical roflumilast formulations aimed at treating psoriasis and other skin conditions. The patent covers the delivery and extended half-life of cream and foam versions of roflumilast, a potent PDE4 inhibitor. CEO Frank Watanabe stated that this patent adds significant protection and validates their dermatology development platform, which is supported by eight existing patents and many pending, projected to last until at least 2037.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced four abstracts on its topical roflumilast program will be presented at the EADV Congress. Roflumilast, a PDE4 inhibitor, is being investigated for treating psoriasis and seborrheic dermatitis. Data from pivotal DERMIS trials show improved efficacy compared to placebo, focusing on alleviating itch severity in chronic plaque psoriasis. Presentation highlights include a Phase 3 study demonstrating the effectiveness of roflumilast cream. The company aims to revolutionize treatment standards in dermatology, with regulatory filings anticipated in late 2021.